ITEMS IN AFP WITH KEYWORD:
Management of difficult-to-treat asthma includes confirming the diagnosis of asthma, addressing contributing factors, and optimizing treatment. An adequate trial of an inhaled corticosteroid and long-acting beta agonist should be implemented with nonbiologic add-on therapies. Nonpharmacologic therapies should also be considered. Management of severe asthma includes assessment of asthma phenotype to determine which patients may benefit from biologic therapy.
Feb 15, 2021 Issue
Intravenous Magnesium Sulfate for Acute Asthma Exacerbation in Children and Adults [Medicine by the Numbers]
Patients who received intravenous magnesium sulfate for acute asthma exacerbation in the emergency department had decreased hospital admissions and no serious adverse effects.
Comprehensive public school–based programs providing supervised administration of asthma medication and/or education for staff, children, and parents markedly decrease asthma-related ED visits for school-aged children.
Oct 1, 2020 Issue
Effects of Inhaled Corticosteroids on Growth in Children with Persistent Asthma [Cochrane for Clinicians]
Inhaled fluticasone (Flovent; 200 mcg per day) is associated with a greater linear growth velocity when compared with beclomethasone (400 mcg per day; an equivalent dose).
Jun 15, 2020 Issue
Asthma: Updated Diagnosis and Management Recommendations from GINA [Practice Guidelines]
The latest update to the Global Initiative for Asthma (GINA) guidelines includes significant changes to treatment recommendations, especially a recommendation against using a short-acting beta2 agonists such as albuterol as sole therapy.
High-quality, office-based spirometry can be as useful and reliable as testing performed in a pulmonary function laboratory. A stepwise approach to spirometry should be used, including assessing for obstruction and reversibility, grading of severity, and referral for full pulmonary testing as indicated.
Patients with mild to moderate asthma only need relief treatment. In this study, patients taking the combination of budesonide/formoterol (Symbicort) as needed had slightly fewer severe exacerbations than patients treated with twice daily budesonide (Pulmicort).
Dupilumab is an effective injectable drug that decreases asthma exacerbations and the need for an oral glucocorticoid in patients with moderate to severe asthma, particularly those with high eosinophil counts.
In these patients with mild asthma (more than one-half used a short-acting beta-agonist [SABA] such as albuterol two or fewer times per week), as-needed use of a combined budesonide/formoterol (Symbicort) inhaler was as effective at preventing exacerbations as daily maintenance budesonide (Pulmicort...
Aug 15, 2019 Issue
Asthma, Back and Neck Pain, Pain During Labor, TIA, CBT for Anxiety [AFP Clinical Answers]
Key clinical questions and their evidence-based answers directly from the journal’s content, written by and for family physicians.